CT7001, an orally bio-available cyclin-dependent kinase 7 (CDK7) selective inhibitor, has shown to be effective in multiple pre-clinical cancer models for many unmet clinical needs, including hormone receptor positive and triple-negative breast cancer. CDK7 acts as a master regulator of transcription and regulates the cell cycle through phosphorylation of members of the CDK family. Carrick first dosed a patient in its Phase 1 clinical trial for CT7001 in November 2017.